{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T13:14:04Z","timestamp":1759497244561,"version":"build-2065373602"},"reference-count":34,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1136\/jitc-2021-003956add1","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T10:00:21Z","timestamp":1752832821000},"page":"e003956add1","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct02715284","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03409614","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03164616","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02504372","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03425643","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05060016","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03800134","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02784171","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04025879","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03703297","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03164616","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03409614","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03409614","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03164616","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03425643","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02504372","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03800134","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04025879","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03703297","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05060016","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03703297","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05060016","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02784171","registry":"10.18810\/clinical-trials-gov"}],"member":"239","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"key":"2025100305421804000_13.7.e003956add1.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.10.002"},{"key":"2025100305421804000_13.7.e003956add1.2","doi-asserted-by":"crossref","first-page":"9016","DOI":"10.1200\/JCO.2021.39.15_suppl.9016","article-title":"Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227","volume":"39","author":"Paz-Ares","year":"2021","journal-title":"JCO"},{"key":"2025100305421804000_13.7.e003956add1.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30167-6"},{"key":"2025100305421804000_13.7.e003956add1.4","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"The Lancet"},{"key":"2025100305421804000_13.7.e003956add1.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32409-7"},{"key":"2025100305421804000_13.7.e003956add1.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03136"},{"key":"2025100305421804000_13.7.e003956add1.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.3062"},{"key":"2025100305421804000_13.7.e003956add1.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00228-2"},{"key":"2025100305421804000_13.7.e003956add1.9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30641-0"},{"key":"2025100305421804000_13.7.e003956add1.10","doi-asserted-by":"crossref","first-page":"v710","DOI":"10.1093\/annonc\/mdz264","article-title":"IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)","volume":"30","author":"Reck","year":"2019","journal-title":"Ann Oncol"},{"key":"2025100305421804000_13.7.e003956add1.11","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)32714-8"},{"key":"2025100305421804000_13.7.e003956add1.12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00975"},{"key":"2025100305421804000_13.7.e003956add1.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302983"},{"key":"2025100305421804000_13.7.e003956add1.14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00518-6"},{"key":"2025100305421804000_13.7.e003956add1.15","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/S0140-6736(23)01613-6","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial","volume":"402","author":"Chu","year":"2023","journal-title":"The Lancet"},{"key":"2025100305421804000_13.7.e003956add1.16","unstructured":"Food and Drug Administration, Bristol-Myers Squibb . OPDIVO (nivolumab) prescribing information. n.d. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=125554"},{"key":"2025100305421804000_13.7.e003956add1.17","unstructured":"Food and Drug Administration, Amgen Inc . IMDELLTRA (tarlatamab) prescribing information. n.d. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&amp;ApplNo=761344"},{"key":"2025100305421804000_13.7.e003956add1.18","unstructured":"Food and Drug Administration, Bristol-Myers Squibb . YERVOY (ipilimumab) prescribing information. n.d. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=125377"},{"key":"2025100305421804000_13.7.e003956add1.19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.9501"},{"key":"2025100305421804000_13.7.e003956add1.20","doi-asserted-by":"publisher","DOI":"10.1084\/jem.182.2.459"},{"key":"2025100305421804000_13.7.e003956add1.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.03.030"},{"key":"2025100305421804000_13.7.e003956add1.22","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000239"},{"key":"2025100305421804000_13.7.e003956add1.23","unstructured":"Food and Drug Administration, Merck Sharp Dohme . KEYTRUDA (pembrolizumab) prescribing information. n.d. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=125514"},{"key":"2025100305421804000_13.7.e003956add1.24","first-page":"93","article-title":"Tremelimumab: First Approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs (Abingdon Engl)"},{"key":"2025100305421804000_13.7.e003956add1.25","unstructured":"Food and Drug Administration, GlaxoSmithKline plc . JEMPERLI (dostarlimab) prescribing information. n.d. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=761174"},{"key":"2025100305421804000_13.7.e003956add1.26","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.jtho.2023.03.008","article-title":"Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial","volume":"18","author":"Makharadze","year":"2023","journal-title":"J Thorac Oncol"},{"key":"2025100305421804000_13.7.e003956add1.27","unstructured":"Food and Drug Administration, Regeneron Pharmaceuticals . LIBTAYO (cemiplimab) prescribing information. n.d. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=761097"},{"key":"2025100305421804000_13.7.e003956add1.28","unstructured":"Food and Drug Administration, AstraZeneca . IMFINZI (durvalumab) prescribing information. n.d. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=761069"},{"key":"2025100305421804000_13.7.e003956add1.29","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.cllc.2024.03.003","article-title":"A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study","volume":"25","author":"Garon","year":"2024","journal-title":"Clin Lung Cancer"},{"key":"2025100305421804000_13.7.e003956add1.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304875"},{"key":"2025100305421804000_13.7.e003956add1.31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2311926"},{"key":"2025100305421804000_13.7.e003956add1.32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404873"},{"key":"2025100305421804000_13.7.e003956add1.33","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.21037\/tlcr-23-115","article-title":"Tarlatamab: the promising immunotherapy on its way from the lab to the clinic","volume":"12","author":"Tang","year":"2023","journal-title":"Transl Lung Cancer Res"},{"key":"2025100305421804000_13.7.e003956add1.34","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2307980"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-003956add1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:42:25Z","timestamp":1759495345000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-003956add1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":34,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,18]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/jitc-2021-003956add1"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-003956add1","relation":{},"ISSN":["2051-1426"],"issn-type":[{"type":"electronic","value":"2051-1426"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}